Newamsterdam Pharma CO NV Form 4 insider transactions

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., sold 105,000 shares of common stock on July 20, 2026.

Louise Frederika Kooij, Chief Accounting Officer at NewAmsterdam Pharma Co. N.V., reported transactions involving the acquisition and disposition of ordinary shares.

Louise Kooij, Chief Accounting Officer at NewAmsterdam Pharma, executed a series of transactions involving the purchase and sale of ordinary shares, including those acquired through stock options, under a Rule 10b5-1 trading plan.

NewAmsterdam Pharma Director Louis G. Lange sold 44,619 ordinary shares in two transactions under a Rule 10b5-1 plan.

NewAmsterdam Pharma CEO Michael H. Davidson has scheduled the exercise of options and subsequent sale of 443,707 ordinary shares for March 2, 2026, under a Rule 10b5-1 plan.

NewAmsterdam Pharma CEO Michael H. Davidson exercised options and sold 306,293 ordinary shares, also transferring 285,715 shares to a Grantor Retained Annuity Trust.

NewAmsterdam Pharma's Chief Scientific Officer and Director, Johannes Jacob Pieter Kastelein, reported selling over $1.6 million in company ordinary shares.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, sold ordinary shares after exercising stock options.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, exercised stock options and subsequently sold a significant number of ordinary shares in late January 2026.

NewAmsterdam Pharma CFO Mayur Ian Somaiya has filed a Form 4 detailing pre-planned stock option exercises and subsequent sales of ordinary shares scheduled for January 2026 under a Rule 10b5-1 plan.

NewAmsterdam Pharma Co N.V. director Hilde Johanna van der Kamp acquired 3,400 restricted stock units and 15,300 stock options.

NewAmsterdam Pharma Director Adele M. Gulfo acquired 3,400 restricted stock units and 15,300 stock options on January 7, 2026.

NewAmsterdam Pharma CEO Michael H. Davidson reported the sale of shares to cover tax obligations and the acquisition of new restricted stock units and stock options.

NewAmsterdam Pharma director William Lewis received grants of 3,400 restricted stock units and options for 15,300 shares.

NewAmsterdam Pharma Director John W. Smither acquired 3,400 restricted stock units and options for 15,300 shares.

NewAmsterdam Pharma Director Mark C. McKenna received grants of 3,400 restricted stock units and options for 15,300 ordinary shares.

NewAmsterdam Pharma's Director, Louis G. Lange, reported the acquisition of 3,400 restricted stock units and 15,300 stock options, alongside a correction to previously reported share ownership.

NewAmsterdam Pharma's Chief Scientific Officer, Johannes Jacob Pieter Kastelein, sold 6,000 shares to cover tax obligations and received new grants of 25,500 restricted stock units and options for 115,000 shares.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, reported a tax-related share sale and significant RSU and option grants.

NewAmsterdam Pharma's CFO, Mayur Ian Somaiya, reported a tax-related share sale and significant new equity awards, including RSUs and stock options.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, exercised stock options and subsequently sold a significant portion of the acquired ordinary shares in late December 2025.

James N. Topper, a Director and 10% owner of NewAmsterdam Pharma Co N.V., acquired 660 ordinary shares indirectly through affiliated entities.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, exercised stock options and subsequently sold a significant portion of the acquired shares.

NewAmsterdam Pharma Director James N. Topper plans to acquire 1,260 ordinary shares at a weighted average price of $24.99 on September 8, 2025, under a 10b5-1 plan.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, sold 18,073 ordinary shares for $25.09 each under a pre-arranged trading plan.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, exercised options to acquire 18,073 ordinary shares.

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, reported the sale of 8,269 ordinary shares for approximately $24.86 per share.

NewAmsterdam Pharma's Chief Scientific Officer, Johannes Jacob Pieter Kastelein, reported planned sales of 100,000 ordinary shares totaling approximately $2.5 million.

James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., purchased 471 ordinary shares indirectly on August 11, 2025.

NewAmsterdam Pharma's Chief Operating Officer, Douglas F. Kling, exercised stock options and subsequently sold a significant number of ordinary shares in pre-planned transactions.